A new vaccine is changing how doctors treat certain skin cancer patients, according to doctors in the ArkLaTex.
Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...
President Donald Trump’s announcement this week of White House aide Heidi Overton as his pick to lead the FDA gave the pharma ...
Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the ...
Early results from final-stage trial of individualised melanoma jab offer hope of more tailor-made cancer treatments ...
Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...
MEXC, a pioneer in 0-fee digital asset trading, has listed the MRNAON/USDT trading pair on Spot, giving users a new ...
Positive Phase 3 KEYTRUDA Results Advance Personalized Melanoma Treatment / cancer, Keytruda, Melanoma, Merck, Moderna, ...
Each patient's vaccine is built from an analysis of the mutations found in that patient's own tumour, CNN reported, rather ...
Merck and Moderna announced positive Phase 3 trial results for their cancer vaccine.Major brokerages upgraded Merck's stock ...
Moderna and Merck said an experimental cancer vaccine paired with Keytruda helped prevent the recurrence of melanoma in a Phase 3 trial. In 2019, a friend noticed a suspicious mole on Angela Evatt's ...
Merck and Moderna's mRNA cancer vaccine hit its Phase 3 trial endpoint, showing improved recurrence-free survival in melanoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results